

RECEIVED
CENTRAL FAX CENTER

NOV 08 2006

Please type a plus sign (+) inside this box → ☐

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/516,500
	Filing Date	3 Feb 04
	First Named Inventor	Juan Luis HANCKE
	Group Art Unit	1625
	Examiner Name	N. RAHMANI, Esq.
Total Number of Pages in This Submission	Attorney Docket Number	HP Ingrid.

ENCLOSURES (check all that apply)		
<input checked="" type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input checked="" type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Licensing-related Papers	<input checked="" type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply-Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Mark Pohl, Esq., USPTO Reg. No. 35,325 Pharmaceutical Patent Attorneys, LLC 55 Madison Avenue, 4th floor, Morristown NJ 07960-7397 USA
Signature	/s/
Date	see below date

CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: <input type="text" value="see below date"/>	
Typed or printed name	
Signature	Date: 8 Nov 06

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/97 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the
United States Patent and Trademark Office Central Fax Center
(571)273-8300

on 8 Nov 06
Date

/Mark Pohl/

Signature

J. Mark Pohl, Reg. No. 35,325

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

The submitted papers are enumerated on the enclosed Transmittal Form,
PTO Form SB/21.

Burden Hour Statement: This form is estimated to take 0.03 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED
CENTRAL FAX CENTER

NOV 08 2006

In The United States Patent Office

5

10

In re Application of Juan Luis HANCKE
et al., *Diterpenic Lambdanes...*

15

Art Unit 1625
Serial No. 10/516,500
Filed 3 February 2004

APPEAL BRIEF

11/08/2006 TL0111 00000084 10516500

01 FC:1402

500.00 0P

APPEAL BRIEF

i

Juan Luis HANCKE OROZCO *et al.*

Serial No. 10/516,500

Priority Date: 03 February 2004

Diterpenic Labdanes . . .

TABLE OF AUTHORITIES

CASES

	<i>In re Angstadt</i> , 537 F.2d 498, 504 (C.C.P.A. 1976) -----	5
5	<i>In re Barr</i> , 444 F.2d 588 (C.C.P.A., 1971) -----	6
	<i>In re Eynde</i> , 480 F.2d 1364, 1370 (C.C.P.A., 1973)-----	6
	<i>In re Fischer</i> , 427 F.2d 833 (C.C.P.A. 1970)-----	5
	<i>In re Wright</i> , 999 F.2d 1557 (Fed. Cir. 1993) -----	8
	<i>Mineral Separation v. Hyde</i> , 242 U.S. 261, 270 (1916)-----	5
10	<i>University of California v. Eli Lilly</i> , 119 F.3d 1559, 1566 (Fed. Cir., 1997)-----	7

OTHER AUTHORITIES

	United States Patent & Trademark Office, <i>Revised Interim Written Description</i>	
15	<i>Guidelines Training Materials</i> -----	8

Juan Luis HANCKE OROZCO *et al.*

Serial No. 10/516,500

Priority Date: 03 February 2004

Diterpenic Labdanes . . .

TABLE OF CONTENTS

	INTRODUCTION.....	1
	REAL PARTY IN INTEREST.....	1
	RELATED APPEALS AND INTERFERENCES.....	1
5	STATUS OF CLAIMS.....	1
	STATUS OF AMENDMENTS.....	1
	SUMMARY OF CLAIMED SUBJECT MATTER.....	2
	GROUND OF REJECTION TO BE REVIEWED ON APPEAL.....	3
	ARGUMENT.....	4
10	THE OFFICE ACTION FAILS TO STATE A <i>PRIMA FACIE</i> CASE OF FAILURE TO PROVIDE AN ENABLING DISCLOSURE.....	4
	THE EXAMINER FAILS TO STATE A <i>PRIMA FACIE</i> CASE THAT CLAIM 73 IS NOT ENABLED.....	4
15	<i>The Examiner Fails To Plead A Prima Facie Case That The Disclosure Fails to Enable the Claim.....</i>	5
	The Applicants' Disclosure is Presumed to Be Enabling.....	5
	The Examiner fails to provide any evidence showing the amount of experimentation required.....	6
	Applicant Provides Evidence That the Claim Is Enabled.....	6
20	THE EXAMINER FAILS TO STATE A <i>PRIMA FACIE</i> CASE THAT CLAIMS 53 TO 73 VIOLATE THE WRITTEN DESCRIPTION REQUIREMENT.....	7
	THE ORIGINAL DISCLOSURE IS PRESUMED TO PROVIDE AN ADEQUATE WRITTEN DESCRIPTION.....	8
25	<i>The Inventors provide several actual reductions to practice.....</i>	8
	<i>The Inventors provide the precise chemical formula at issue.....</i>	9
	THE EXAMINER FAILS TO REBUT THIS PRESUMPTION.....	9
	<i>The Examiner fails to provide a reasonable <i>factual</i> basis for the rejection.....</i>	9
30	THE EXAMINER FAILS TO STATE A <i>PRIMA FACIE</i> CASE OF ANTICIPATION OF CLAIMS 53 TO 73.....	11
	THE EXAMINER FAILS TO COMPARE THE PRIOR ART TO THE CLAIMS.....	11
	NO PENDING REJECTION IS SUSTAINABLE.....	15

Juan Luis HANCKE OROZCO *et al.*
Serial No. 10/516,500
Priority Date: 03 February 2004
Diterpenic Labdanes . . .

CLAIMS APPENDIX	16
EVIDENCE APPENDIX.....	19
RELATED APPEALS APPENDIX	20

5

Juan Luis HANCKE OROZCO *et al.*
Serial No. 10/516,500
Priority Date: 03 February 2004
Diterpenic Labdanes . . .

INTRODUCTION

This APPEAL BRIEF is submitted pursuant to the earlier-submitted NOTICE OF APPEAL. Enclosed please find the large-entity fee for filing an appeal brief. This APPEAL BRIEF is filed within two months of the earlier-submitted
5 NOTICE OF APPEAL. No extension of time fee is therefore believed due.

This patent application has been granted Special status. Expedited resolution of this appeal is therefore respectfully requested.

Real Party In Interest

The real party in interest is HP Ingredients, Inc., a Florida corporation.

Related Appeals and Interferences

10 There are no related appeals nor interferences known to appellant, the appellant's legal representative, nor the assignee which may be related to, directly affect nor be directly affected by or have a bearing on the Board's decision in the immediate appeal.

Status of Claims

15 Claims 1 to 52 stand cancelled. Claims 53 to 73 are pending and stand twice rejected. Appellant appeals the rejection of all pending claims.

Status of Amendments

No amendment has been filed subsequent to the Final rejection.

Juan Luis HANCKE OROZCO *et al.*


Serial No. 10/516,500

Priority Date: 03 February 2004

Diterpenic Labdanes . . .Summary of Claimed Subject Matter

The invention relates to a compound (3-[2-[decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-naphthalenyl]ethylidene]-dihydro-4-hydroxy-2(3h)-furanone) and its use to treat certain medical conditions.

The inventors believe that this compound is effective in modulating the activity of the human immune system, and will therefore be effective in treating conditions exhibiting an under-active or over-active immune response. Three independent claims are pending.



Independent claim 53 claims the use of 3-[2-[decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-naphthalenyl] ethylidene]-dihydro-4-hydroxy-2(3h)-furanone to treat autoimmune disease, Acquired Immune

Juan Luis HANCKE OROZCO *et al.*

Serial No. 10/516,500

Priority Date: 03 February 2004

Diterpenic Labdanes . . .

Deficiency Syndrome or Alzheimer's Disease. *See e.g.*, SPECIFICATION at 13:1 *et seq.*; 2:23 *et seq.*; 6:9 *et seq.*¹

Independent claim 66 claims the use of 3-[2-[decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-naphthalenyl]ethylidene]-dihydro-4-hydroxy-2(3h)-furanone to modulate a patient's immune system function (e.g., to activate peroxysome proliferator activated receptor γ . *E.g.*, *id.* at 6:9 *et seq.*

Independent claim 73 claims the use of 3-[2-[decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-naphthalenyl]ethylidene]-dihydro-4-hydroxy-2(3h)-furanone to treat "syndrome X," a condition which the inventors believe is caused by immune system dysfunction. *E.g.*, *id.* at claim 73.

Grounds of Rejection to be Reviewed on Appeal

The grounds for rejection presented on appeal are as follows:

Whether the OFFICE ACTION states a *prima facie* case that claim 73 is not enabled?

Whether the OFFICE ACTION states a *prima facie* case that claims 53 to 73 fail to comply with Section 112, first paragraph?

Whether the OFFICE ACTION states a *prima facie* case that claims 53 to 73 are anticipated under Section 102(b)?

¹ To avoid confusion, all references to the Specification are to the clean (not the black lined) version of the SUBSTITUTE SPECIFICATION received by the Office on 02 December 2004.

Juan Luis HANCKE OROZCO *et al.*

Serial No. 10/516,500

Priority Date: 03 February 2004

Diterpenic Labdanes . . .Argument

Applicant respectfully believes the Examiner has failed to provide a sustainable rationale to reject any claim. The claims argued separately are placed under sub-headings including the relevant claim number. Applicant here quotes the 16 March 2006 OFFICE ACTION rather than the 31 August 2006 FINAL OFFICE ACTION, when the FINAL ACTION simply states that the rejections are maintained “for the reasons of record.”

THE OFFICE ACTION FAILS TO STATE A *PRIMA FACIE* CASE OF
FAILURE TO PROVIDE AN ENABLING DISCLOSURE

The Examiner fails to state a prima facie case that claim
73 is not enabled

Claim 73 covers a method comprising: i) identifying in a person the possible presence of Syndrome X, and ii) administering to said person:

Andrographis paniculata; or an *Andrographis paniculata* extract containing 3-[2-[decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-naphthalenyl]ethylidene]-dihydro-4-hydroxy-2(3h)-furanone.

The Examiner rejects claim 73 for non-enablement. The Examiner argues, “*Andrographis paniculata* grown just anywhere everywhere on this planet may or may not have the compounds necessary to treat Syndrome X. Does this

Juan Luis HANCKE OROZCO *et al.*

Serial No. 10/516,500

Priority Date: 03 February 2004

Diterpenic Labdanes . . .

extract of this plant, grown under any and all conditions, treat Syndrome X?" See
OFFICE ACTION (31 August 2006) at 2.

Applicant respectfully asks the Board to reverse this rejection because
the Examiner fails to state a *prima facie* case of non-enablement, nor provide any
evidence to support her rejection.

*The Examiner Fails To Plead A Prima Facie
Case That The Disclosure Fails to Enable
the Claim*

*The Applicants' Disclosure is Presumed to Be
Enabling*

Applicant's disclosure is presumed as a matter of law to be operative
and enabling. See *In re Wright*, 999 F.2d 1557, 1562 (Fed. Cir. 1993).
Furthermore, as long as the disclosure provides at least one method of making the
claimed product, then the enablement requirement is satisfied. *In re Fischer*, 427
F.2d 833, 839 (C.C.P.A. 1970).

In the immediate case, the Specification provides at, *e.g.*, 17:15 to
25:29, "at least one method" of making the extract of claim 73. Thus, the
Specification enables one to practice this claim as a matter of law. See *In re
Fischer*.

Juan Luis HANCKE OROZCO *et al.*

Serial No. 10/516,500

Priority Date: 03 February 2004

Diterpenic Labdanes . . .

*The Examiner fails to provide any evidence
showing the amount of experimentation required*

Furthermore, a *prima facie* case of non-enablement requires the

Examiner to introduce into the record evidence showing that the amount of
5 experimentation required to make the claimed invention is "undue." *E.g., Mineral
Separation v. Hyde*, 242 U.S. 261, 270 (1916); *In re Angstadt*, 537 F.2d 498, 504
(C.C.P.A. 1976). The Board cannot sustain a rejection where the Examiner has not
bothered to provide evidentiary support for it. *See e.g., In re Eynde*, 480 F.2d
1364, 1370 (C.C.P.A., 1973); *In re Barr*, 444 F.2d 588 (C.C.P.A., 1971); *In re*
10 *Ahert*, 424 F.2d 1088, 1091 (C.C.P.A., 1970).

In the immediate case, the OFFICE ACTION fails to provide any
evidence at all showing the amount of experimentation required. To the contrary,
the Examiner merely speculates that experimentation may be required – *yet might
not be*. ("Andrographis paniculata grown just anywhere everywhere on this planet
15 may or my not have the compounds necessary") Such speculation fails to replace
evidence showing the amount of experimentation required.

*Applicant Provides Evidence That the Claim Is
Enabled*

Furthermore, one of the Inventors of record specifically contradicts
20 the Examiner's baseless speculation, testifying:

APPEAL BRIEF - Page 6

Juan Luis HANCKE OROZCO *et al.*

Serial No. 10/516,500

Priority Date: 03 February 2004

Diterpenic Labdanes . . .

I have no reason to believe that "*Andrographis paniculata* ... may or my [*sic*] not have the compounds necessary to treat Syndrome X." To the contrary, every specimen of *Andrographis paniculata* which I have evaluated, from whatever source or ecosystem, has in fact contained "the compounds necessary to treat Syndrome X." I therefore know of no factual evidence to support the thesis that *Andrographis paniculata* from a certain specific ecosystem "may or my [*sic*] not have the compounds necessary to treat Syndrome X."

See J. L. HANCKE, RULE 132 DECLARATION (9 September 2006) at ¶ 4 (emphasis mine). The Board cannot rely on the Examiner's speculation because it is *baseless* and is specifically *contradicted* by the Inventor.

THE EXAMINER FAILS TO STATE A PRIMA FACIE CASE THAT CLAIMS
53 TO 73 VIOLATE THE WRITTEN DESCRIPTION REQUIREMENT

Claims 53 to 73 stand rejected under 35 U.S.C. 112, first paragraph "for reason of record." See OFFICE ACTION at 2, ¶ 4 (31 August 2006). The reason of record is an alleged failure to comply with the "written description" requirement. See OFFICE ACTION at 4, ¶ 7 (16 March 2006). Applicant respectfully asks the Board to reverse the Examiner because she has not bothered to provide you with the evidence needed to sustain her rejection.

Juan Luis HANCKE OROZCO *et al.*

Serial No. 10/516,500

Priority Date: 03 February 2004

Diterpenic Labdanes . . .

The Original Disclosure Is
Presumed To Provide An
Adequate Written Description

*The Inventors provide several actual
reductions to practice*

5 The description may fulfill the written description requirement in a
number of ways. For example, if the disclosure contains an actual reduction to
practice, then the disclosure fulfills the written description requirement. *See*
10 *Regents of the University of California v. Eli Lilly*, 119 F.3d 1559, 1566 (Fed. Cir.,
1997), *certiorari denied*, 523 U.S. 1089 (1998). (possession may be shown by
describing an actual reduction to practice"). Thus, the Patent Office's own
Guidelines say that where the disclosure contains an actual reduction to practice,
this fulfills the requirement, and the Examiner should stop the analysis there. *See*
United States Patent & Trademark Office, *Revised Interim Written Description*
15 *Guidelines Training Materials* at page 7.

In the immediate case, the Examiner does not dispute that the
disclosure at *e.g.*, pages 23 to 34, teaches actual reductions to practice. Thus, the
original disclosure provides an adequate written description. *See Eli Lilly*.

Juan Luis HANCKE OROZCO *et al.*

Serial No. 10/516,500

Priority Date: 03 February 2004

Diterpenic Labdanes

*The Inventors provide the precise chemical
formula at issue*

Alternatively, chemical formulae provide adequate written
description. *See Eli Lilly* at 1568 (“In cases involving chemical materials, generic
5 formulae usually indicate with specificity what the generic claims encompass”).

In the immediate case, the Examiner does not dispute that the
disclosure clearly teaches the specific formula for the claimed compound.

*The Examiner Fails To Rebut
This Presumption*

10 A written description as filed is presumed adequate. *See In re Wright*,
999 F.2d 1557, 1562 (Fed. Cir. 1993). Given the presumption of adequacy, the
burden is on the Examiner to provide a *reasonable factual basis* to challenge the
adequacy of the written description. *See* MANUAL OF PATENT EXAM. PROC. §
2163.04. Thus, the Examiner “has the initial burden of presenting by a
15 preponderance of the evidence why a person skilled in the art would not recognize
in an applicant’s disclosure a description of the invention defined by the claims.”
Id.

*The Examiner fails to provide a reasonable
factual basis for the rejection*

20 In the immediate case, the Examiner fails to provide a *reasonable
factual basis* to challenge the adequacy of the written description. To the contrary,

Juan Luis HANCKE OROZCO *et al.*
Serial No. 10/516,500
Priority Date: 03 February 2004
Diterpenic Labdanes . . .

the Examiner provides *no factual basis at all* to support its allegation that the claims contain “subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s) . . . had possession of the claimed invention.” Rather, the Examiner argues that the disclosure fails to provide a written description of something *different from* the claimed invention.

For example, the Examiner argues that “the specification does not enable the instant compound to alter the gene expression.” See OFFICE ACTION (16 March 2006) at 6, 11, 14, 18, 22. “Altering gene expression,” however, is not at issue here; to the contrary, the claims do not even mention “altering gene expression.”

Similarly, the Examiner argues that “Applicant has not provided written description on how to diagnose a patient with any and all possible diseases known.” See OFFICE ACTION (16 March 2006) at 5; *id.* at 6 (“the specification does not enable the instant compound to . . . treat any and all known or unknown diseases”). This argument, however, is inapposite, because the claims at issue do not cover “any and all known or unknown diseases”; to the contrary, the claims enumerate specific

Juan Luis HANCKE OROZCO *et al.*

Serial No. 10/516,500

Priority Date: 03 February 2004

Diterpenic Labdanes . . .

diseases (AIDS, Syndrome X, et cetera) known as, or suspected to be, disorders affecting the immune system.²

THE EXAMINER FAILS TO STATE A *PRIMA FACIE* CASE OF
ANTICIPATION OF CLAIMS 53 TO 73.

5 Claims 53 to 73 stand rejected as anticipated over John G. BABISH *et al.*, WO/96/17605 (1996); John G. BABISH *et al.*, U.S. Patent Publication No. 2002/0068098 (2002); Srinivas NANDURI *et al.*, U.S. Patent Publication No. 2002/0016324 (2002); Srinivas NANDURI *et al.*, U.S. Patent No. 6,410,590 (2002); Srinivas NANDURI *et al.*, U.S. Patent No. 6,486,196 (2002); Geoffrey D.
10 WHEELOCK *et al.*, U.S. Patent No. 5,833,994 (1998); and Geoffrey D. WHEELOCK *et al.*, WO 98/30213 (1998).

Reconsideration is requested because the rather voluminous art of record fails to teach the claimed compound.

The Examiner fails to compare the prior art to the claims

15 The Examiner argues that "Andrographolide is well known in the art." The claims, however, do not require "andrographolide." Rather, the claims cover 3-

² Furthermore, the Examiner concedes that the art teaches diagnostic methods for each of the specific diseases at issue here. See OFFICE ACTION (16 March 2006) at 8, 20 ("autoimmune diseases, ... AIDS, etc. can be diagnosed by methods comprising determining from a sample ... an abnormally decreased or increased level of TR6 polypeptide or TR6 mRNA."). Because diagnostic methods are known in the art, Applicant need not provide an enabling disclosure of them.

Juan Luis HANCKE OROZCO *et al.*

Serial No. 10/516,500

Priority Date: 03 February 2004

Diterpenic Labdanes . . .



[2-[decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-naphthalenyl]ethylidene]-dihydro-4-hydroxy-2(3h)-furanone. This distinction is important because there is some confusion in the art regarding the meaning of the term "andrographolide." See J.L. HANCKE, RULE 132 DECLARATION (9 September 2006) at ¶ 6. Pointedly, the Examiner herself acknowledges that her own references confirm this. See OFFICE ACTION at 4 ("It is noted that Babish et al., 2002/0077350, and US 2002/0068098 have incorrect structure for Andrographolide.")

The claimed compound, 3-[2-[decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-naphthalenyl]ethylidene]-dihydro-4-hydroxy-2(3h)-furanone, is not taught by any reference of record. This is illustrated in the accompanying Figure:





Juan Luis HANCKE OROZCO *et al.*

Serial No. 10/516,500

Priority Date: 03 February 2004

Diterpenic Labdanes...John G. BABISH *et al.*, WO '605

The claimed compound

John G. BABISH *et al.*, U.S. '098
G.D. WHEELLOCK *et al.*, U.S. '994, U.S. '063
and WO '213NANDURI *et al.*, U.S. '324NANDURI *et al.*, U.S. '196NANDURI *et al.*, U.S. '590

For example, BABISH *et al.*, WO '605 and NANDURI *et al.*, U.S. '324, U.S. '590, and U.S. '196 (2002) fail to teach methylation at C4. Similarly, BABISH *et al.* U.S. '098, and WHEELLOCK *et al.*, U.S. '994, U.S. '063 and WO '213 fail to teach oxidation at C9. No art of record teaches the claimed compound. See J.L. HANCKE, RULE 132 DECLARATION (9 September 2006) at ¶¶ 7-9; J.L. HANCKE, SUPPLEMENTAL RULE 132 DECLARATION (20 September 2006) at ¶¶ 1-4.

Further, the Examiner concedes that the predictability in the pharmaceutical art is low, because minor structural differences can precipitate major

Juan Luis HANCKE OROZCO *et al.*

Serial No. 10/516,500

Priority Date: 03 February 2004

Diterpenic Lubdunés . . .

changes in toxicology or clinical efficacy. This shows that it would not have been obvious to modify any of the prior art compounds to *make* the claimed compound, and that it would not have been obvious to *use* such a modified compound for the claimed uses.

5 Similarly, the claims are drawn to methods to treat AIDS, Syndrome X, non-autoimmune Alzheimer's Disease, and autoimmune disease. In contrast, the art of record fails to teach these therapeutic uses. See J.L. HANCKE, RULE 132 DECLARATION (9 September 2006) at ¶¶ 7-9.

10

Juan Luis HANCKE OROZCO *et al.*

Serial No. 10/516,500

Priority Date: 03 February 2004

*Diterpenic Labdanes . . .***NO PENDING REJECTION IS SUSTAINABLE**

The claims are in condition for allowance. The Examiner has not bothered to try to provide the Board with the evidence the Board would need to sustain the Examiner's rejections.

Applicant therefore respectfully requests the Board reverse all pending rejections and order the Examiner to issue a NOTICE OF ALLOWANCE.

Respectfully submitted on behalf of the Applicant by its attorneys,
PHARMACEUTICAL PATENT ATTORNEYS, LLC

/s/

Mark Pohl, Reg. No. 35,325

Pharmaceutical Patent Attorneys LLC

55 Madison Avenue, 4th floor

Morristown, NJ 07960-6397 USA

8 November 2006

SD:\USV\10.879.816-Remarks (July 05).doc

Juan Luis HANCKE OROZCO *et al.*

Serial No. 10/516,500

Priority Date: 03 February 2004

Diterpenic Labdanes . . .

CLAIMS APPENDIX

53. A method comprising:

i) diagnosing in a patient a disease selected from the group consisting of: Alzheimer's Disease; Acquired Immune Deficiency Syndrome; and autoimmune disease, and

ii) administering to said patient 3-[2-[decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-naphthalenyl]ethylidene]-dihydro-4-hydroxy-2(3h)-furanone in an amount effective to combat said disease.

54. The method of claim 53, wherein said disease comprises autoimmune disease.

55. The method of claim 54, wherein said autoimmune disease comprises rheumatoid arthritis.

56. The method of claim 54, wherein said autoimmune disease comprises lupus exanthematous.

57. The method of claim 54, wherein said autoimmune disease comprises multiple sclerosis.

58. The method of claim 54, wherein said autoimmune disease comprises asthma.

59. The method of claim 54, wherein said autoimmune disease comprises allergic reaction.

60. The method of claim 54, wherein said autoimmune disease comprises a condition selected from: systemic dermatomyocytis; and psoriasis.

Juan Luis HANCKE OROZCO *et al.*

Serial No. 10/516,500

Priority Date: 03 February 2004

Diterpenic Labdanes . . .

61. The method of claim 54, wherein said autoimmune disease comprises osteoarthritis.

62. The method of claim 54, wherein said autoimmune disease comprises diabetes mellitus.

5 63. The method of claim 54, wherein said an amount effective to combat said disease comprises from about 1 mg to about 5 mg of 3-[2-[decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-naphthalenyl]ethylidene]-dihydro-4-hydroxy-2(3h)-furanone per day, per kilogram of patient body weight.

10 64. The method of claim 53, wherein said disease comprises Alzheimer's Disease.

65. The method of claim 53, wherein said disease comprises Acquired Immune Deficiency Syndrome.

66. A method comprising:

- 15 i) diagnosing in a patient a disease, and
- ii) administering to said patient 3-[2-[decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-naphthalenyl]ethylidene]-dihydro-4-hydroxy-2(3h)-furanone in an amount effective to affect said patient's immune system function.

20 67. The method of claim 66, wherein said amount effective comprises an amount effective to activate peroxysome proliferator activated receptor γ .

68. The method of claim 66, wherein said amount effective comprises an amount effective to reduce the activity of an inflammatory cytokine.

69. The method of claim 68, said inflammatory cytokine comprising interleukin-2.

Juan Luis HANCKE OROZCO *et al.*

Serial No. 10/516,500

Priority Date: 03 February 2004

Diterpenic Labdanes...

70. The method of claim 68, said inflammatory cytokine comprising interferon γ .

71. The method of claim 66, wherein said amount effective comprises an amount effective to inhibit NF κ B.

5 72. The method of claim 66, wherein said amount effective comprises an amount effective to inhibit T-cell proliferation.

73. A method comprising:

i) identifying in a person the possible presence of Syndrome X, and

ii) administering to said person a substance selected from the group

10 consisting of: *Andrographis paniculata*; and an *Andrographis paniculata* extract containing 3-[2-[decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-naphthalenyl]ethylidene]-dihydro-4-hydroxy-2(3h)-furanone; said substance administered in an amount effective to combat Syndrome X.

15

Juan Luis HANCKE OROZCO *et al.*

Serial No. 10/516,500

Priority Date: 03 February 2004

Diterpenic Labdanes . . .

EVIDENCE APPENDIX

The two Rule 132 Declarations previously submitted in this case, and all other evidence relied on, has been submitted before filing of the NOTICE OF APPEAL. Physical copies of this evidence is not included here because the Board

5 has access to this evidence via the PAIR system.

Juan Luis HANCKE OROZCO *et al.*

Serial No. 10/516,500

Priority Date: 03 February 2004

Diterpenic Labdanes . . .

RELATED APPEALS APPENDIX

None.

5